|
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 |
|
Age (y)/sex | 63/F | 64/F | 69/M | 12/M | 7 months/M | 4/M | 3/M |
|
Underlying disease | AML | Unknown | MDS | Relapsed ALL | SCID | Stage 4 neuroblastoma | AML |
|
Type of transplant | Reduced intensity Allogeneic HSCT from MUD | Nonmyeloablative Allogeneic HSCT | Allogenic HSCT | Double cord | Single cord | Autologous HSCT | MUD peripheral blood HSCT |
|
GVHD | Day 24 | Chronic | Chronic | None | None | None | None |
|
Immune suppression for GVHD | Corticosteroids Mycophenolate mofetil | Prednisone Sirolimus | Prednisone | None | None | None | None |
|
Onset of PIV | | | | | | | |
URTI | URTI: TxD + 89 | | | URTI: TxD + 260 | URTI: TxD + 71 | URTI: TxD + 26 | URTI: TxD + 2 |
LRTI | LRTI: TxD + 124 | 6 y SP SCT | LRTI: TxD + 240 | LRTI: TxD + 275 | LRTI: TxD + 2 | LRTI: TxD + 25 | |
|
Type of PIV | PIV3 | PIV1 | PIV3 | PIV3 | PIV2 | PIV3 | PIV3 |
|
Radiographic findings | Tree in bud opacities, mild diffuse bronchial thickening consistent with viral bronchiolitis on CT | Ground glass opacities on CT | Ground glass opacities on CT | Ground glass opacities on CXR/CT | Infiltrates on CXR/CT | New infiltrates on CXR/CT | |
|
Clinical symptoms | Cough, dyspnea, increased oxygen requirements | Respiratory distress, increased oxygen requirements | Fever, hemoptysis, and respiratory distress | Respiratory distress, increased oxygen requirements | Fever, wheezing, and increased oxygen requirements | Fever, cough, and crackles | Cough, rhinorrhea |
|
Copathogens | Reactivated CMV viremia (prior to PIV URTI) | None | None | Adenovirus and hMPV (at time of URTI) HRV and Adenovirus (at time of LRTI) | None | None | HRV |
|
Mechanical ventilation | None | Intubated | Intubated | None | None | None | None |
|
DAS181 treatment | 10 mg/day × 3 days (dry inhaled powder) | 3.2 mg/day × 3 days (nebulized) and then 4.5 mg/day × 2 days (nebulized and face mask) | 3.2 mg/day × 3 days and then 4.5 mg/day × 2 days (nebulized) | 10 mg/day × 10 days (dry powder) | 0.14 mg/kg per day × 2 days and then 0.2 mg/kg per day × 3 days (nebulized) | 0.14 mg/kg per day × 2 days and then 0.2 mg/kg per day × 3 days (nebulized) | 0.14 mg/kg per day × 10 days (nebulized) |
|
Maximum alkaline phosphatase while on treatment, IU/L (normal range) | Not reported | 240 (35–104) | 169 (35–104) | 477 (135–530) | 298 (95–380) | 598 (95–380) | 247 (95–380) |
|
Outcome | Died of relapsed AML | Died | Alive | Alive | Alive | Alive | Alive |
|
Year/reference | 2011 [11] | 2014 [10] | 2014 [10] |
2015 [14] | 2015 [14] | 2015 [14] | 2015 [14] |
|